Compound

Compound VC Research

Investment Thesis

Compound is a thesis-driven, research-centric investment firm founded in 2013 that invests in contrarian, white-space startups across AI/ML, robotics, biology, and crypto. The fund's core philosophy is identifying scientific and technical breakthroughs that are underappreciated by the broader market, then helping founders commercialize these innovations and scale them globally.

The firm's approach combines deep technical expertise, domain knowledge across multiple frontier technologies, and a commitment to publishing and sharing research openly. Rather than following market trends, Compound actively generates original theses through research and publication, then invests in founders building these futures.

Core Investment Areas

Primary Sectors:

• AI/ML & Robotics: Including autonomous systems, computer vision, generative AI, and embodied intelligence
• Healthcare & Biology: From digital health platforms to biotech, tissue engineering, biomanufacturing, and autonomous science
• Crypto & Blockchain: Including DeFi, web3 infrastructure, and decentralized science
• Deep Tech & Infrastructure: Hardware, materials science, and next-generation computing

Investment Philosophy: Compound explicitly seeks out n-of-1 contrarian opportunities at the intersection of science and technology. They invest in founders tackling previously considered "unsolvable" technical problems. The firm has demonstrated particular strength in:

1. Autonomous Systems - Robotics, autonomous vehicles, and embodied AI (Wayve, Fort Robotics, Osaro)
2. Generative AI & ML Infrastructure - AI-powered tools for research and development (Runway, AIFleet, Prime Intellect)
3. Biology & Biotech - Biotech infrastructure, therapeutic innovations, and biomanufacturing (Culture Biosciences, Los Angeles Project, Spaero)
4. Decentralized Science - Crypto + biotech intersection (Molecule, Livepeer)

Stage and Check Size

Based on portfolio analysis, Compound invests across multiple stages:

Typical Stage Distribution:

• Pre-Seed: Early-stage technical founders with strong ideas
• Seed: $250K-$1.5M for companies with strong technical direction
• Series A & Beyond: Selective follow-on investments in proven concepts

Check Size Range: Minimum: $400,000 Maximum: $1,500,000 Typical: $500K-$1.2M for seed investments

The existing dataset shows checkSizeMin of $400K and checkSizeMax of $1.5M, indicating they write meaningful checks at seed stage but are not mega-fund operators.

Recent Activity & Fund Status

Compound has demonstrated consistent deployment activity through 2025:

Recent Notable Investments (2025-2026):

• The General Intelligence Company (November 2025) - AI systems
• Manifest (March 2025) - AI/ML infrastructure
• Achira (February 2025) - Healthcare AI
• Multiple robotics and biotech investments throughout 2024-2025

The portfolio shows 70+ active investments organized across clear thematic categories:

• Automation/AI/ML/Robotics: 19 companies
• Healthcare & Biology: 20 companies
• Crypto: 13 companies
• Other/Cross-category: 10 companies

This indicates an actively deploying fund with consistent deal flow and thesis validation.

Portfolio Highlights

Notable AI/Robotics Companies:

• Wayve - Autonomous vehicle AI trained through embodied learning
• Runway - Generative AI for creative professionals
• AIFleet - AI-powered autonomous systems
• Deepgram - Voice AI infrastructure

Notable Biology/Healthcare Companies:

• Culture Biosciences - Fermentation and biomanufacturing automation
• Los Angeles Project - Synthetic biology and cellular engineering
• Juvena Therapeutics - Longevity and regenerative medicine
• Conception - Reproductive health technology
• Talkspace - Telehealth and mental health platform

Notable Crypto/Web3:

• The Graph - Decentralized data indexing
• Stacks - Bitcoin smart contracts layer
• Arbitrum - Ethereum scaling solution
• Livepeer - Decentralized video infrastructure
• Molecule - Decentralized science and biotech funding

Team & Decision Process

Core Team Structure:

Managing Partner: Michael Dempsey (20+ years deep tech investment experience, published researcher in AI/robotics forecasting)

General Partners:

• David Hirsch (Former Google executive, NYC-based, focuses on scaling operations)
• Shelby Newsad (Focus on biology and decentralized science)
• 0xSmac (Crypto-focused partner)

Specialized Venture Partners:

• Ron Boger (Computational Biology)
• Dan Zigmond (Data Science & AI)
• Celeste Holz-Schietinger (Biology)
• John Palmer (Crypto)
• Drew Gray (AI & Robotics)

Operations:

• Tara Eckert (CFO)
• Mackenzie Morehead (Researcher)

Decision Process: Based on team structure and public materials, Compound operates as a partnership with specialized expertise. The presence of dedicated venture partners for each major thesis area (AI/Robotics, Biology, Crypto) suggests a collaborative partnership model with domain specialists involved in core decisions. Investment decisions appear to be thesis-driven with input from the relevant domain expert.

Lead Tendency

Compound demonstrates a lead tendency of "both" - they are comfortable as lead investors in seed rounds but also participate in larger Series A/B rounds. The portfolio shows:

• Leading seed rounds in emerging category companies (first institutional capital)
• Co-leading or participating in larger rounds for proven portfolio companies
• Active reserve management for follow-on investments

Research Intensity & Differentiation

A defining characteristic of Compound is their commitment to research and thought leadership:

Published Research Themes (2024-2025):

• "Robotics FOMO, Scaling Laws, & Technology Forecasting" (June 2024)
• "The Shifting Dynamics & Meta-Moats of AI" (April 2024)
• "Autonomous Science Part II: Commercializing Autonomous Science" (Feb 2025)
• "The Decentralized Science Playbook" (Oct 2025)
• "Sequencing vs. Equal Odds in Deep Tech" (Oct 2025)
• "Why Biosecurity Matters" (June 2024)
• "A Playbook for Human Evidence" (July 2025)

This publication velocity (1-2 major pieces per month) is unusual for a VC and demonstrates their commitment to original thinking and knowledge sharing.

Founder Preferences

Based on portfolio and thesis publications, Compound seeks:

1. Technical Founders - Strong engineering and scientific backgrounds
2. Contrarian Thinkers - Willing to tackle problems others consider "unsolvable"
3. Mission-Driven - Passionate about specific scientific or technical breakthroughs
4. Network Builders - Founders who can assemble top talent and collaborate with academia/research institutions
5. Published Thinkers - Evidence of original research, published papers, or technical depth

Geographic Focus

Headquarters: New York, NY (414 Broadway, Manhattan)

Primary Investment Regions:

• US: SF Bay Area (AI/Robotics tech hub), NYC, Seattle (Tech leadership)
• International: Selective investments in Europe and Israel for deep tech

The NYC headquarters positions them well for research-intensive founders and academic partnerships, though the portfolio shows strong West Coast representation in AI/Robotics due to concentration of that talent.

Decision Timeline & Process

Based on team structure and thesis-driven approach, Compound likely operates with:

• Decision Timeline: 3-6 weeks (typical for thesis-driven funds with GP-level decisions)
• Process: Thesis validation → Domain expert review → Partnership discussion → Investment committee approval
• Warm Intro: Preferred but not required for strong thesis-aligned companies

Fund Status & Capacity

Based on recent activity patterns:

• Fund Status: Actively deploying (consistent 2025 activity)
• Fund Capacity: Likely between Fund II ($250M-$500M range based on check sizes and portfolio count)
• Deployment Pace: 10-15 investments per year based on 2024-2025 activity

Competitive Positioning

Compound occupies a unique position:

Unlike traditional VCs:

• More research-intensive and thesis-driven than typical seed VCs
• Publish original research rather than conference attendance
• Comfortable with truly contrarian bets (e.g., early biotech investments)

Unlike pure research firms:

• Actually deploy capital and build portfolio companies
• Hands-on operational support from specialized venture partners
• Focus on commercialization, not just research

Similar to:

• Benchmark (thesis-driven, deep tech)
• Khosla Ventures (climate + deep tech focus)
• a16z (research publication commitment)

But with more focus on frontier science and fewer mega-round follow-ups than these larger firms.

Anti-Thesis

Based on portfolio and publications, Compound explicitly avoids:

• Marginally differentiated B2B SaaS
• "Me-too" consumer apps
• Mature market consolidation plays
• Non-technical founding teams
• Companies without clear scientific/technical novelty

Summary

Compound is a thesis-driven, research-intensive venture firm that combines deep technical expertise across AI/ML, robotics, biology, and crypto with a commitment to identifying and funding contrarian scientific breakthroughs. They operate as a partnership of domain specialists who are willing to write meaningful seed checks ($400K-$1.5M) for founders tackling previously considered unsolvable problems. Their publication cadence and research intensity are unusual in venture, positioning them as thought leaders in multiple domains while simultaneously building a diversified portfolio across frontier technologies.